Novartis

Novartis Reports Results of Ofatumumab (OMB157) in P-III ASCLEPIOS Trials for Relapsing Multiple Sclerosis

August 6, 2020August 6, 2020Tuba Khan

Shots: The two P-III studies, ASCLEPIOS I & II involves assessing of ofatumumab (20mg, monthly SC) vs teriflunomide (14mg) in 1882 patients aged [Read More...]

Novartis Reports Results of Kymriah (tisagenlecleucel) in P-II ELARA Study for Follicular Lymphoma

August 4, 2020August 4, 2020Tuba Khan

Shots: The P-II ELARA study involves assessing the efficacy and safety of Kymriah in adult patients with r/r FL across 12 countries in [Read More...]

PharmaShots Weekly Snapshot (Jul 27- 31, 2020)

August 3, 2020August 3, 2020Tuba Khan

1. Oxford Biomedica Signs Three Year Clinical Supply Agreement with Axovant to Manufacture and Supply AXO-Lenti-PD for Parkinson’s Disease Published: Jul 31, 2020 | [Read More...]

Insights+ Exclusive: COVID-19 Healthcare News Monthly Updates – July 2020

July 31, 2020July 31, 2020Shiwani Sharma

Our planet is facing a major pandemic outbreak due to COVID-19 and health agencies are taking every measure to stop it. The COVID-19 [Read More...]

Sangamo Highlights its Genomic Medicine Pipeline at R&D Day 2019

Sangamo Signs a Worldwide License Agreement with Novartis to Develop Genomic Therapies for Three Neurodevelopmental Targets

July 30, 2020July 30, 2020Shiwani Sharma

Shots: Sangamo to receive $75M upfront within 30 days, $720M milestone payments including up to $420M in development milestones and up to $300M [Read More...]

Novartis’ Enerzair Breezhaler Receives the EC’s Approval as a Maintenance Treatment of Asthma in Adult Patients Uncontrolled with LABA/ICS

July 7, 2020July 7, 2020Shiwani Sharma

Shots: The approval is based on P-III IRIDIUM study assessing Enerzair Breezhaler (qd) vs Atectura Breezhaler (QMF149; IND/MF) in 3092 patients in the [Read More...]